Eli Lilly (LLY) Q2 2026: Realized Price Subtracted 36 Points Outside the U.S.

Eli Lilly grew revenue 48% last quarter while realized prices fell. The filing breaks the increase into its parts, and every point of it came from volume: units added 60 points, realized price subtracted 13, and currency added 1. Outside the United States the trade was starker still — volume contributed 113 percentage points while realized price subtracted 36 percentage points, as Mounjaro entered China's national reimbursement list and launched across new markets. For a franchise whose valuation rests on the durability of obesity drug economics, that decomposition is the number worth reading, and it appears nowhere in the earnings headline.

1. Half of a $29.8 Billion Balance Sheet Expansion Was Bought in June

Lilly added $29.8 billion of assets in six months — more than a quarter of the base it started the year with — and roughly half of that growth arrived through three acquisitions that closed in June.

1-1. Intangibles Nearly Tripled, and Three Deals Explain Almost All of It

In the table below, the line that matters is "other intangibles." Cash and PP&E grew at a pace broadly consistent with a business compounding at 50%; accounts receivable grew at 13.1%, below the revenue growth rate.

The $11.6 billion jump in intangibles ties almost exactly to three business combinations. Centessa added $6,058 million of acquired in-process R&D, Kelonia $4,695 million, and Ventyx $977 million — $11,730 million in total. Their goodwill contributions of $1,655 million, $1,052 million and $232 million sum to $2,939 million, against a reported goodwill increase of $2,951 million. Two of the three closed on June 24 and June 25, meaning they sit on the balance sheet but contributed essentially nothing to the quarter's revenue.

Inventory deserves a second look. At $16,793 million against quarterly cost of sales of $3,268 million, stock now represents roughly 468 days of cost. Work in process is $9,997 million of the $16,755 million replacement-cost total. This is consistent with a deliberate pre-build for launches rather than a demand miss. Receivable days stand at about 80. The LIFO adjustment is immaterial at $38 million, so the inventory figure is close to current cost.

1-2. Debt Rose $12.4 Billion in a Half-Year That Generated $16 Billion of Cash

Total debt reached $54.9 billion at June 30, up from $42.5 billion at year-end. The gross new borrowings were of two kinds: Lilly issued $9.0 billion of notes in May with maturities from 2028 to 2066 and coupons between 4.150% and 5.700%, including $1.3 billion of floating-rate paper tied to SOFR, and drew $5,284 million of commercial paper, against zero at December 31; repayments of existing debt partially offset those additions.

The maturity profile is unusually long for a borrower this size, and the mark tells you why that matters. Carrying value of long-term debt is $49,624 million against a fair value of $46,555 million — the existing stack is worth $3.1 billion less than its book value, which is a benefit to Lilly, not a cost. Backstopping the paper is $10.0 billion of unused committed bank credit.

Operating liabilities moved far less. Accounts payable rose 13.6% to $6,112 million — well short of the 33% growth in quarterly cost of sales, meaning Lilly is not funding the build-out through its suppliers. The exception is contingent consideration, which went from $251 million to $2,518 million on the Kelonia deal. Maximum potential milestone payments on Kelonia and Centessa alone reach $3,750 million and $1,542 million.

1-3. Retained Earnings Carried the Equity; Paid-In Capital Went Backwards

Equity rose 27.7% to $33,879 million. Retained earnings grew 30.3% to $31,893 million on $14,491 million of first-half profit. Additional paid-in capital fell 3.1% to $7,117 million — not because of buybacks, which are charged to retained earnings, but because $591 million of net share repurchases under employee stock plans outweighed $362 million of stock-based compensation credits. Accumulated other comprehensive loss narrowed slightly to $2,761 million as currency translation improved. Diluted weighted-average share count fell from 900.0 million a year ago to 893.6 million in Q2 2026.

2. Gross Margin Improved and Reported Profit Growth Still Halved

The operating business got meaningfully better in the quarter. What happened below the operating lines is what cut reported growth from 48% to 25%.

2-1. Before the Deal Charges, Profit Grew About 1.6 Times Faster Than Sales

Read the table from the middle out. The "profit before acquired IPR&D and special charges" line is the operating engine; the two lines under it are what the quarter's dealmaking took away.

Profit before deal charges rose 77.4% on 47.7% revenue growth — operating leverage of about 1.6 times. Every one percent of sales growth produced 1.6 percent of profit growth. The margin on that line widened 9.1 percentage points to 54.2%.

This is genuine fixed-cost absorption, not accounting. R&D grew 14% while revenue grew 48%, dropping research intensity from 21.4% of sales to 16.6%. Marketing and administrative costs grew 25%, half the rate of sales, even while supporting the U.S. launch of Foundayo. Gross margin rose 1.5 points to 85.8% on better production cost and mix, absorbing the lower realized prices.

2-2. Where 48% Turned Into 25%

Three items closed the gap. Acquired IPR&D charges were $2,776 million against $154 million a year ago, largely from the Orna and Ajax asset purchases. Asset impairment and restructuring charges were $703 million against nothing, primarily deal-related transaction costs and integration charges. Together they removed $3,325 million more from pretax profit than the comparable quarter.

The third item is tax. Because acquired IPR&D charges are not deductible, the effective rate jumped to 23.3% from 16.5%. On pretax profit of $8,978 million, that 6.8-point increase cost roughly $610 million of net income. Diluted EPS rose 26.2% against net income growth of 25.3%, so buybacks added roughly one point. Almost all of the EPS gain came from operations, not from shrinking the share count.

For context on trajectory: full-year 2024 revenue was $45,043 million with $10,590 million of net income; 2025 was $65,179 million and $20,640 million. First-half 2026 alone has produced $42,773 million and $14,491 million.

3. Cash Conversion Crossed 1.0, and It Still Was Not Enough

Operating cash flow more than tripled and Lilly still ended the half-year with $12.4 billion more debt. Look at the last two lines together.

Earnings quality has genuinely turned. Operating cash flow covered 111% of net income in the first half, against 56% a year earlier. It came despite receivables and inventory absorbing $5.4 billion of cash. Part of the improvement is structural: acquired IPR&D is charged against reported profit, while much of the cash for those deals sits in investing outflows.

Capital intensity is holding steady rather than rising. Expenditures for long-lived assets were 12.5% of revenue, against 12.4% a year ago, even as Lilly builds out global manufacturing. This is growth capex scaling with the business, not a step change.

The allocation math is where the debt comes from. Free cash flow was $10,679 million. Dividends took $3.1 billion and buybacks $4.0 billion, leaving about $3.6 billion. Business development consumed $13.3 billion — roughly 3.7 times what was left. The $9.0 billion bond deal and the commercial paper draw closed the gap. Stock-based compensation, at $362 million, is a rounding error against $42.8 billion of revenue.

4. Generics Have Now Been Filed Against 65% of the Revenue Base

Mounjaro and Zepbound were 65% of first-half revenue, up from 52% in the first half a year ago — and 65% of the second quarter alone, against 55% in the year-ago quarter. That concentration is the central fact of this business, and the filing discloses two separate clocks running against it.

In July 2026, multiple generic manufacturers filed abbreviated applications seeking to market copies of Mounjaro and Zepbound before the listed patents expire. Lilly says it intends to sue. These cases typically take years, but the clock has started on the compound behind two-thirds of revenue.

The second clock is statutory. Jardiance is already subject to government-set Medicare prices in 2026. Trulicity and Verzenio were selected in January 2026 with government-set prices taking effect in 2028. Verzenio faces a separate clock as well: Cipla filed an ANDA in April 2026, and Lilly sued in Delaware in June. Separately, the Medicare GLP-1 Bridge program began offering discounted obesity medicines on July 1, 2026, and Lilly states plainly that uptake is unknown.

On other litigation, the disclosure language is worth noting. For most proceedings Lilly says it "cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued." The Federal Circuit reversed a favorable Emgality ruling in April 2026, prompting a charge in the first quarter. The Supreme Court declined review of the average manufacturer price verdict in May. Product liability claims over incretin medicines are consolidated in two federal multidistrict proceedings.

Research spending needs a US GAAP caveat. Lilly expenses all R&D immediately and cannot capitalize it, so reported margins are structurally more conservative than those of an IFRS-reporting peer. Including acquired IPR&D, Lilly directed 28.7% of second-quarter revenue toward research — more than the 22.4% a year ago, even as internal R&D intensity fell.

5. The Trade Lilly Is Making, and What Would Break It

What grew was volume, and it grew everywhere. Revenue outside the United States rose 80% in the quarter to $8,561 million, with Europe up 60% and China up 102%. The operating engine improved alongside it — gross margin at 85.8%, pre-charge operating margin at 54.2%, cash conversion above 1.0.

What carries risk is the price line. A 13-point consolidated price drag, and a 36-point drag abroad, is the cost of that volume. So far the trade has been overwhelmingly positive, because volume added 60 points against it. The question is what happens when volume growth normalizes while the pricing concessions — China reimbursement listing, U.S. cash-pay reductions, the Medicare Bridge program, IRA-set prices from 2028 — remain permanent. Inventory at 468 days and manufacturing capex at 12.5% of sales both assume volume keeps compounding.

Capital allocation has shifted decisively toward acquisition. In the first half, Lilly spent $13.3 billion on business development against $7.1 billion returned to shareholders and $5.3 billion of capex. Three more deals closed in July for about $2.0 billion, with up to $3.9 billion committed, and the pending AtaiBeckley purchase adds roughly $2.8 billion at closing. Buyback capacity is down to $7.0 billion under the current share repurchase authorization.